이뮤놈(IMNM)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $23.97 (+0.17%), 시가총액 $2.36B, 52주 범위 $7.92 ~ $26.97.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335.
이뮤놈의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
이뮤놈의 현재 주가는 $23.97 (+0.17%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
이뮤놈의 시가총액은 약 $2.36B입니다.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United…